Erythropoietin and renoprotection

被引：64

作者：

Bahlmann, Ferdinand H. ^{[1
]}

Fliser, Danilo ^{[1
]}

机构：

[1] Univ Saarland, Med Ctr, Dept Internal Med 4, D-66421 Homburg, Germany

来源：

CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION | 2009年 / 18卷 / 01期

关键词：

acute kidney injury; apoptosis; chronic kidney disease; erythropoietin; NITRIC-OXIDE SYNTHASE; ACUTE-RENAL-FAILURE; DIFFERENTIATED NEUROBLASTOMA SH-SY5Y; MESSENGER-RNA EXPRESSION; SMOOTH-MUSCLE-CELL; DARBEPOETIN-ALPHA; PLATELET REACTIVITY; IN-VITRO; KIDNEY; RECEPTOR;

D O I：

10.1097/MNH.0b013e32831a9dde

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

In the haematopoietic system, the principal function of erythropoietin (EPO) is the regulation of RBC production. Consequently, following the cloning of the EPO gene, recombinant human EPO (rHuEPO) forms have been widely used for treatment of anaemia in chronic kidney disease and chemotherapy-induced anaemia in cancer patients. However, a steadily growing body of evidence indicates that the therapeutic benefits of rHuEPO could be far beyond the correction of anaemia. Several articles have been recently published on the tissue-protective, nonhaematological effects of rHuEPO that prevent ischaemia-induced tissue damage in several organs including the kidney. In this review, we focus on nonhaematological effects of rHuEPO in various experimental settings of acute and chronic kidney injury. Because this tissue-protective action of rHuEPO is not the result of correction of anaemia-related tissue hypoxia, we will also discuss potential molecular pathways involved. Finally, we will review the current literature on clinical studies with rHuEPO or analogous substances and progression of chronic kidney disease, and propose possible clinical renoprotective strategies.

引用

页码：15 / 20

页数：6

共 77 条

[21] Erythropoietin mRNA expression in human fetal and neonatal tissue
Dame, C
Fahnenstich, H
Freitag, P
Hofmann, D
Abdul-Nour, T
Bartmann, P
Fandrey, J
[J]. BLOOD, 1998, 92 (09) : 3218 - 3225
[22] Normalization of hemoglobin level in patients with chronic kidney disease and anemia
Drueke, Tilman B.
Locatelli, Francesco
Clyne, Naomi
Eckardt, Kai-Uwe
Macdougall, Iain C.
Tsakiris, Dimitrios
Burger, Hans-Ulrich
Scherhag, Armin
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (20) : 2071 - 2084
[23] Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression
Eto, N.
Wada, T.
Inagi, R.
Takano, H.
Shimizu, A.
Kato, H.
Kurihara, H.
Kawachi, H.
Shankland, S. J.
Fujita, T.
Nangaku, M.
[J]. KIDNEY INTERNATIONAL, 2007, 72 (04) : 455 - 463
[24] EPO: renoprotection beyond anemia correction
Fliser, Danilo
Bahlmann, Ferdinand H.
Haller, Hermann
[J]. PEDIATRIC NEPHROLOGY, 2006, 21 (12) : 1785 - 1789
[25] Mechanisms of disease: erythropoietin - an old hormone with a new mission?
Fliser, Danilo
Bahlmann, Ferdinand H.
deGroot, Kirsten
Haller, Hermann
[J]. NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2006, 3 (10): : 563 - 572
[26] Minireview: Receptor dimerization in GH and erythropoietin action - It takes two to tango, but how?
Frank, SJ
[J]. ENDOCRINOLOGY, 2002, 143 (01) : 2 - 10
[27] FRASER JK, 1988, EXP HEMATOL, V16, P836
[28] A role for erythropoietin in the attenuation of radiocontrast-induced acute renal failure in rats
Goldfarb, Marina
Rosenberger, Christian
Shina, Ahuva
Rosen, Seymour
Heyman, Samuel N.
[J]. RENAL FAILURE, 2006, 28 (04) : 345 - 350
[29] EPO and α-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney
Gong, H
Wang, WD
Kwon, TH
Jonassen, T
Li, CL
Ring, T
Frokiær, J
Nielsen, S
[J]. KIDNEY INTERNATIONAL, 2004, 66 (02) : 683 - 695
[30] Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial
Gouva, C
Nikolopoulos, P
Ioannidis, JPA
Siamopoulos, KC
[J]. KIDNEY INTERNATIONAL, 2004, 66 (02) : 753 - 760

← 1 2 3 4 5 6 7 8 →